Department of Medicine, University of Udine, Udine, Italy; Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
Department of Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy; Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy.
Cancer Treat Rev. 2023 Nov;120:102624. doi: 10.1016/j.ctrv.2023.102624. Epub 2023 Sep 7.
Endocrine therapy is one of the standard adjuvant treatments to reduce the risk of recurrence and mortality in patients with hormone receptor positive early breast cancer. Despite its proven efficacy, ET side effects, which persist over time even if low grade, may deteriorate quality of life. During follow-up visits, emphasis is generally placed on the risk of disease recurrence, while the topic of ET side effects is commonly neglected and discussed only briefly. This could lead to poor adherence to therapy and early treatment discontinuation, resulting in worse survival outcomes. The aim of this review is to provide an overview of the available evidence on the incidence and reporting of ET-related side effects (including vasomotor symptoms, musculoskeletal disorders and genitourinary syndrome of menopause, as well as fatigue, psychological and ocular disorders, dysmetabolic effects and loss of bone density) and of the pharmacological and non-pharmacological strategies available to mitigate symptom burden.
内分泌治疗是降低激素受体阳性早期乳腺癌患者复发和死亡风险的标准辅助治疗之一。尽管其疗效已得到证实，但即使是低级别，ET 副作用也会持续存在，从而降低生活质量。在随访期间，通常会强调疾病复发的风险，而 ET 副作用的问题通常被忽视，只是简要讨论。这可能导致治疗依从性差和提前停药，从而导致生存结局更差。本综述的目的是提供关于 ET 相关副作用（包括血管舒缩症状、肌肉骨骼疾病和绝经后泌尿生殖系统综合征，以及疲劳、心理和眼部疾病、代谢紊乱和骨密度丧失）发生率和报告的现有证据概述，并介绍减轻症状负担的药理学和非药理学策略。
